Bhubaneswar: COVID-19 vaccine would be produced at Bharat Biotech International Limited’s unit at Andharua in Odisha capital, said company’s Chairman and Managing Director Dr Krishna Ella today during a high-level meeting held on digital mode and chaired by Chief Secretary Asit Tripathy from Lok Seva Bhawan here.
An advanced and vibrant vaccine manufacturing unit was put on fast track with the Chief Secretary resolving the issues and directing to start the ground level construction work within a fortnight and commence production within the schedule time.
Further, Tripathy directed the anchor developer Bharat Biotech International Ltd (BBIL) to set up a ‘state of art’ biotech incubation center, common facilities and IT corridor along with the first phase construction of the industry. The company was requested to promote the local startups.
Secretary, Skill Development and Technical Education and Chairman & Managing Director IDCO Sanjay Kumar Singh apprised, “The land is readily available at Biotech Park, Andharua for groundbreaking works. The building plan as per the design has also been approved”.
Dr Krishna Ella said, “BBIL’s unit at Andharua in Bhubaneswar would produce ten types of vaccines including malaria and COVID. The total investment would be around Rs 300 crore. Best of the technology will be put in the unit”.
The Chief Secretary assured that the company would be provided all support for future expansion of the unit at Andharua.